Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas

P. J. Loehrer, S. D. Williams, L. H. Einhorn, R. Ansari

Research output: Contribution to journalArticle

54 Scopus citations


From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide. Ifosfamide was administered at a dose of 1.25 to 1.5 g/m2 daily for five consecutive days with courses repeated every three weeks. If no serious toxicity was noted, subsequent dosages were escalated to a maximum of 2.0 g/m2/d. In addition, N-acetylcysteine (NAC) (8 to 12 g/d) was administered (in divided daily doses days 1 through 7) as a urothelial protective agent. Nausea and vomiting occurred in the majority of the treated patients. Other toxicities noted were mild myelosuppression, CNS toxicity, and one case of acute renal failure. One complete response (CR) and five partial responses (PR) were observed in 27 evaluable patients (CRs and PRs = 22%). Ifosfamide has definite activity against pancreatic adenocarcinoma. Doses > 1.2 g/m2 for days 1 through 5 can be administered without significant toxicity in the majority of patients. Further trials with ifosfamide alone and/or with other agents are warranted.

Original languageEnglish (US)
Pages (from-to)367-372
Number of pages6
JournalJournal of Clinical Oncology
Issue number3
StatePublished - 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas'. Together they form a unique fingerprint.

  • Cite this